{"id":5050,"date":"2019-05-16T13:26:18","date_gmt":"2019-05-16T07:56:18","guid":{"rendered":"https:\/\/www.delveinsight.com\/blog\/?p=5050"},"modified":"2021-07-24T12:57:21","modified_gmt":"2021-07-24T07:27:21","slug":"the-business-cocktail-bayers-biologics","status":"publish","type":"post","link":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics","title":{"rendered":"Ginkgo to buy mining platform; Vertex, Kymera collaborate; ArcherDX nets $60M; Bayer to invest $150M"},"content":{"rendered":"<div id=\"ez-toc-container\" class=\"ez-toc-v2_0_76 counter-hierarchy ez-toc-counter ez-toc-white ez-toc-container-direction\">\n<p class=\"ez-toc-title\" style=\"cursor:inherit\">Table of Contents<\/p>\n<label for=\"ez-toc-cssicon-toggle-item-6a07b01f7a5b8\" class=\"ez-toc-cssicon-toggle-label\"><span class=\"\"><span class=\"eztoc-hide\" style=\"display:none;\">Toggle<\/span><span class=\"ez-toc-icon-toggle-span\"><svg style=\"fill: #999;color:#999\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" class=\"list-377408\" width=\"20px\" height=\"20px\" viewBox=\"0 0 24 24\" fill=\"none\"><path d=\"M6 6H4v2h2V6zm14 0H8v2h12V6zM4 11h2v2H4v-2zm16 0H8v2h12v-2zM4 16h2v2H4v-2zm16 0H8v2h12v-2z\" fill=\"currentColor\"><\/path><\/svg><svg style=\"fill: #999;color:#999\" class=\"arrow-unsorted-368013\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" width=\"10px\" height=\"10px\" viewBox=\"0 0 24 24\" version=\"1.2\" baseProfile=\"tiny\"><path d=\"M18.2 9.3l-6.2-6.3-6.2 6.3c-.2.2-.3.4-.3.7s.1.5.3.7c.2.2.4.3.7.3h11c.3 0 .5-.1.7-.3.2-.2.3-.5.3-.7s-.1-.5-.3-.7zM5.8 14.7l6.2 6.3 6.2-6.3c.2-.2.3-.5.3-.7s-.1-.5-.3-.7c-.2-.2-.4-.3-.7-.3h-11c-.3 0-.5.1-.7.3-.2.2-.3.5-.3.7s.1.5.3.7z\"\/><\/svg><\/span><\/span><\/label><input type=\"checkbox\"  id=\"ez-toc-cssicon-toggle-item-6a07b01f7a5b8\"  aria-label=\"Toggle\" \/><nav><ul class='ez-toc-list ez-toc-list-level-1 ' ><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-1\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics\/#Ginkgo_announces_to_buy_Warp_Drive_Bios_genome_mining_platform\" >Ginkgo announces to buy Warp Drive Bio\u2019s genome mining platform<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-2\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics\/#Vertex_Kymera_collaborates_to_develop_Protein_Degradation_Medicine\" >Vertex, Kymera collaborates to develop Protein Degradation Medicine &nbsp;<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-3\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics\/#ArcherDX_nets_USD_60_M_to_advance_Minimum_Residual_Disease_diagnostics\" >ArcherDX nets USD 60 M to advance Minimum Residual Disease diagnostics<\/a><\/li><li class='ez-toc-page-1 ez-toc-heading-level-4'><a class=\"ez-toc-link ez-toc-heading-4\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics\/#Bayer_to_invest_USD_150_M_for_building_a_new_therapy_facility\" >Bayer to invest USD 150 M for building a new therapy facility<\/a><\/li><\/ul><\/nav><\/div>\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Ginkgo_announces_to_buy_Warp_Drive_Bios_genome_mining_platform\"><\/span><strong>Ginkgo announces to buy Warp Drive Bio\u2019s genome mining platform <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Ginkgo Bioworks<\/strong> has announced to acquire the genome mining platform from <strong>Warp Drive Bio<\/strong>, a subsidiary of <strong>REVOLUTION Medicines<\/strong>.&nbsp; The acquisition will give Gingko access to Warp Drive Bio&#8217;s <strong>genome mining team, technology, and database<\/strong>. This collaboration will help merge biological information and advance its applications in other pharmaceutical industry. The Genome mining platform will augment Ginkgo\u2019s sequencing capabilities, biological codebase, bioinformatics and machine learning tools for gene discovery.<\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Vertex_Kymera_collaborates_to_develop_Protein_Degradation_Medicine\"><\/span><strong>Vertex, Kymera collaborates to develop Protein Degradation Medicine &nbsp;<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Vertex Pharmaceuticals<\/strong>&#8211; best known for its <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/cystic-fibrosis-market\">Cystic Fibrosis<\/a><\/strong> clinical development- is going to form an alliance with <strong>Kymera Therapeutics<\/strong> to accelerate the therapeutic market of different diseases, beyond<a href=\"https:\/\/www.delveinsight.com\/report-store\/cystic-fibrosis-transmembrane-conductance-regulators-cftr-pipeline-insight\"> Cystic Fibrosis<\/a>. Vertex will pay Kymera USD 70 million upfront. Vertex so far has been focusing on developing drugs for<strong> rare genetic diseases<\/strong> caused due to mutations. And this deal will pave the way for Vertex to enter into the world of Protein degradation. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"ArcherDX_nets_USD_60_M_to_advance_Minimum_Residual_Disease_diagnostics\"><\/span><strong>ArcherDX nets USD 60 M to advance Minimum Residual Disease diagnostics<\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>ArcherDX<\/strong> successfully has raised <strong>USD 60 million<\/strong> to advance in the clinical development of <strong>minimum residual disease<\/strong> giving the company an opportunity to ingress into a market worth more than USD 20 million. Furthermore, the funds will accelerate the clinical development of its companion diagnostic program spanning solid and blood tumours, as well as circulating tumour DNA tests. <\/p>\n\n\n\n<h4 class=\"wp-block-heading\"><span class=\"ez-toc-section\" id=\"Bayer_to_invest_USD_150_M_for_building_a_new_therapy_facility\"><\/span><strong>Bayer to invest USD 150 M for building a new therapy facility <\/strong><span class=\"ez-toc-section-end\"><\/span><\/h4>\n\n\n\n<p><strong>Bayer <\/strong>has adhered to spend <strong>USD150 million <\/strong>to build a new facility for Biologics development and manufacturing. The Cell Culture Technology Center to be built on Bayer&#8217;s campus in Berkeley, California, will focus primarily on biologic therapies for <strong><a href=\"https:\/\/www.delveinsight.com\/report-store\/gene-therapy-in-oncology-innovation-to-commercialization-competitive-landscape\">oncology<\/a><\/strong>, <strong>cardiology <\/strong>and additional speciality care areas. The new facility will leverage automation, digital capabilities and single-use bioprocessing technologies to allow faster production of medicines.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Ginkgo announces to buy Warp Drive Bio\u2019s genome mining platform Ginkgo Bioworks has announced to acquire the genome mining platform from Warp Drive Bio, a subsidiary of REVOLUTION Medicines.&nbsp; The acquisition will give Gingko access to Warp Drive Bio&#8217;s genome mining team, technology, and database. This collaboration will help merge biological information and advance its [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":5054,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_editorskit_title_hidden":false,"_editorskit_reading_time":0,"_editorskit_is_block_options_detached":false,"_editorskit_block_options_position":"{}","advgb_blocks_editor_width":"","advgb_blocks_columns_visual_guide":"","footnotes":""},"categories":[32],"tags":[4014],"industry":[17225],"therapeutic_areas":[17228,17243],"class_list":["post-5050","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-notizia","tag-ginkgo-bioworks","industry-pharmaceutical","therapeutic_areas-oncology","therapeutic_areas-respiratory-diseases"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.8 (Yoast SEO v25.8) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Ginkgo to buy mining platform; Vertex, Kymera collaborate<\/title>\n<meta name=\"description\" content=\"Bayer has adhered to spend USD150 million to build a new facility for Biologics development and manufacturing. The Cell Culture Technology Center to be..\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ginkgo to buy mining platform; Vertex, Kymera collaborate\" \/>\n<meta property=\"og:description\" content=\"Bayer has adhered to spend USD150 million to build a new facility for Biologics development and manufacturing. The Cell Culture Technology Center to be..\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics\" \/>\n<meta property=\"og:site_name\" content=\"DelveInsight Business Research\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/\" \/>\n<meta property=\"article:published_time\" content=\"2019-05-16T07:56:18+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2021-07-24T07:27:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17141119\/16-May-business.png\" \/>\n\t<meta property=\"og:image:width\" content=\"647\" \/>\n\t<meta property=\"og:image:height\" content=\"345\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"DelveInsight\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:site\" content=\"@DelveInsight\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"DelveInsight\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Ginkgo to buy mining platform; Vertex, Kymera collaborate","description":"Bayer has adhered to spend USD150 million to build a new facility for Biologics development and manufacturing. The Cell Culture Technology Center to be..","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics","og_locale":"en_US","og_type":"article","og_title":"Ginkgo to buy mining platform; Vertex, Kymera collaborate","og_description":"Bayer has adhered to spend USD150 million to build a new facility for Biologics development and manufacturing. The Cell Culture Technology Center to be..","og_url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics","og_site_name":"DelveInsight Business Research","article_publisher":"https:\/\/www.facebook.com\/DelveInsight-1423323754607782\/","article_published_time":"2019-05-16T07:56:18+00:00","article_modified_time":"2021-07-24T07:27:21+00:00","og_image":[{"width":647,"height":345,"url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17141119\/16-May-business.png","type":"image\/png"}],"author":"DelveInsight","twitter_card":"summary_large_image","twitter_creator":"@DelveInsight","twitter_site":"@DelveInsight","twitter_misc":{"Written by":"DelveInsight","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics","url":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics","name":"Ginkgo to buy mining platform; Vertex, Kymera collaborate","isPartOf":{"@id":"https:\/\/www.delveinsight.com\/blog\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics#primaryimage"},"image":{"@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics#primaryimage"},"thumbnailUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17141119\/16-May-business.png","datePublished":"2019-05-16T07:56:18+00:00","dateModified":"2021-07-24T07:27:21+00:00","author":{"@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a"},"description":"Bayer has adhered to spend USD150 million to build a new facility for Biologics development and manufacturing. The Cell Culture Technology Center to be..","inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/the-business-cocktail-bayers-biologics#primaryimage","url":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17141119\/16-May-business.png","contentUrl":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17141119\/16-May-business.png","width":647,"height":345,"caption":"The Business cocktail 16 may"},{"@type":"WebSite","@id":"https:\/\/www.delveinsight.com\/blog\/#website","url":"https:\/\/www.delveinsight.com\/blog\/","name":"DelveInsight Business Research","description":"Blog","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.delveinsight.com\/blog\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/5fbf6ca478835d03fdb5e17d905b520a","name":"DelveInsight","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.delveinsight.com\/blog\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/afdd550c64e18f6ad8957080b017c6ae55f4916951d641d3cd40264176aa0e86?s=96&d=mm&r=g","caption":"DelveInsight"}}]}},"author_meta":{"display_name":"DelveInsight","author_link":"https:\/\/www.delveinsight.com\/blog\/author\/gtadmin"},"featured_img":"https:\/\/assets.delveinsight.com\/blog\/wp-content\/uploads\/2019\/05\/17141119\/16-May-business-300x160.png","coauthors":[],"tax_additional":{"categories":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Notizia - Recent Pharma, Healthcare and Biotech Happenings<\/span>"]},"tags":{"linked":["<a href=\"https:\/\/www.delveinsight.com\/blog\/notizia\/\" class=\"advgb-post-tax-term\">Ginkgo Bioworks<\/a>"],"unlinked":["<span class=\"advgb-post-tax-term\">Ginkgo Bioworks<\/span>"]}},"comment_count":"0","relative_dates":{"created":"Posted 7 years ago","modified":"Updated 5 years ago"},"absolute_dates":{"created":"Posted on May 16, 2019","modified":"Updated on Jul 24, 2021"},"absolute_dates_time":{"created":"Posted on May 16, 2019 1:26 pm","modified":"Updated on Jul 24, 2021 12:57 pm"},"featured_img_caption":"The Business cocktail 16 may","series_order":"","_links":{"self":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5050","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/comments?post=5050"}],"version-history":[{"count":0,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/posts\/5050\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media\/5054"}],"wp:attachment":[{"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/media?parent=5050"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/categories?post=5050"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/tags?post=5050"},{"taxonomy":"industry","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/industry?post=5050"},{"taxonomy":"therapeutic_areas","embeddable":true,"href":"https:\/\/www.delveinsight.com\/blog\/wp-json\/wp\/v2\/therapeutic_areas?post=5050"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}